Although preliminary, our findings suggest that hyperleptinemia, by favoring expansion of pathogenic Fel d1-specific CD4+ T cells and impairing the functioning of regulatory CD4+ T cell subsets, would not only exacerbate disease severity, but also negatively impacts the success of allergen-specific immunotherapies against cat allergies (56, 57). The gene discussed is CD4; the disease is allergic disease.